CD68 and obesity due to melanocortin 4 receptor deficiency: Notably, therapeutic propagermanium administration did not result in decreased expression of total macrophage marker (CD68) or increased M2 macrophage marker expression, indicating that decreasing pro-inflammatory M1 macrophage content is sufficient to improve obesity-associated insulin resistance.